There are currently no upcoming events.

Corporate Profile

Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease.

The company’s Orbital Atherectomy Systems treat calcified and fibrotic plaque in arterial vessels throughout the leg and heart in a few minutes of treatment time, and address many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives.

The U.S. FDA granted 510(k) clearance for the use of the Diamondback Orbital... More >>

Recent News

More >>
Cardiovascular Systems CEO to Take Medical Leave 11/16/15
Cardiovascular Systems (CSI) (NASDAQ: CSII) said today that, effective Dec. 1, 2015 , Chief Executive Officer David L. Martin will take a medical leave of absence for approximately three months to focus on his cancer treatment. While Martin is on leave, Scott Ward , currently Chairman of the Board of Directors, will serve as Chairman and Interim Chief Executive Officer. CSI announced on September 14, 2015, that Martin is undergoing treatment for stomach cancer. At this point in his treatment regimen, he will undergo surgery, followed by additional chemotherapy. Martin said, “Scott’s extensive experience in medical technology and role as CSI Chairman make him an excellent selection for interim Chief Executive Officer. With Scott and our executive management team’s leadership, I can concentrate on my remaining treatment and recovery. This cancer can be cured, and I plan to return as CEO in March 2016.” Ward became a member of CSI's Board of Directors in 2013 and was named Chairman in...
More >>
Cardiovascular Systems Reports Fiscal 2016 First-Quarter Financial Results 11/04/15
Conference Call Scheduled for Today, November 4, 2015, at 3:45 PM CT (4:45 PM ET) Revenues of $43.9 million and net loss of $(0.41) per share were in line with preliminary results guidance range Company enrolls first patients in OPTIMIZE study LIBERTY 360° study update provided at VIVA Conference; enrollment exceeds 1,100, including over 600 patients with Rutherford classification stages of 4, 5 and 6 TRUTH study demonstrates that CSI’s Orbital Atherectomy System is effective at reducing and modifying calcium Cardiovascular Systems, Inc. (CSI) (NASDAQ:CSII), a medical device company developing and commercializing innovative interventional treatment systems for peripheral and coronary artery disease, today reported financial results for its fiscal first quarter ended September 30, 2015, that were in line with the preliminary results reported on October 7, 2015. The company’s first quarter revenues of fiscal 2016 were $43.9 million , an 11% increase from $39.5 million in the fiscal...
More >>